Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities

TUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced a new partnership with the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner Program. The collaboration is designed to support the advancement of manufacturing of adeno-associated adenovirus (AAV), as well as other cell and gene therapy (CGT) programs within the state of California. With $5.5 billion in funding from the state of California, CIRM is accelerating world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world.

Under terms of the partnership, Avid has joined the CIRM Industry Resource Partner Program to provide development and CGMP manufacturing services to CIRM-funded programs. The company will assist CIRM’s partners in accelerating gene therapy development and manufacturing through its suite of CDMO services, which span process and analytical development, cell banking, virus banking, drug substance manufacturing, and fill-finish activities. CIRM-funded programs will be offered access to Avid’s services in order to reduce the timelines required to advance through clinical development. All partnership activities will be performed in Avid’s recently launched, world-class CGT CGMP manufacturing facility in Orange County, California.

“CIRM was established with a mission to provide treatments to patients with unmet medical needs through the promise of cell and gene therapy. As a proud California-based company, Avid Bioservices is excited to be collaborating with CIRM to help fulfill this vision through our strong development capabilities, established quality systems and proven commercial manufacturing experience in support of delivering these treatments to patients in need,” said Drew Brennan, general manager, viral technologies of Avid Bioservices.